All Updates

All Updates

icon
Filter
Partnerships
MilliporeSigma and The Michael J. Fox Foundation partner to advance Parkinson's research
Precision Medicine
Jun 18, 2024
Last week:
M&A
Nscale acquires Kontena to enhance HPC and AI infrastructure capabilities
Generative AI Infrastructure
Yesterday
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Product updates
Together AI unveils new inference stack and endpoints for improved speed and efficiency
Generative AI Infrastructure
Jul 20, 2024
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Product updates
Micron Technology introduces high-performance MRDIMMs to improve bandwidth for AI and HPC applications
Generative AI Infrastructure
Jul 19, 2024
Management news
Bionano Genomics receives Nasdaq non-compliance notice; continues trading efforts
Precision Medicine
Jul 19, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Precision Medicine

Precision Medicine

Jun 18, 2024

MilliporeSigma and The Michael J. Fox Foundation partner to advance Parkinson's research

Partnerships

  • MilliporeSigma and The Michael J. Fox Foundation for Parkinson's Research (MJFF) have partnered to research treatments to slow down the progression of Parkinson's disease (PD).

  • According to the partnership, MilliporeSigma will use its SMCxPRO immunoassay technology to detect low levels of pS65 ubiquitin, a biomarker associated with cell dysfunction in PD patients. This technology will help track the response of different therapeutic options on disease progression, potentially contributing to improved quality of life for patients. The study will be funded by MJFF. 

  • MilliporeSigma, Merck KGaA's life science business, was formed from the merger of EMD Millipore and Sigma-Aldrich. It offers a comprehensive portfolio of life sciences products, including biochemicals, labware, and equipment for various scientific and industrial applications. MilliporeSigma focuses on accelerating access to health by providing tools for research, drug discovery, development, and manufacturing.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.